Y-400

N/A

Report date: 2023/06/20 20:00:54

Base Information

Drug NameY-400
Drug Alias NameY-400
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAngiopoietin-2 inhibitorsVascular endothelial growth factor A inhibitors
TargetsAngiopoietin-2Vascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesWuhan Yzy Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShenzhen KangzheWeisheng Pharmaceutical Development Co LtdChongqing Lummy Pharmaceutical Co LtdWuhan Yzy Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A